The global rare disease genetic testing market size is expected to reach USD 1.8 Billion by 2027 according to a new study by Polaris Market Research. The report “Rare Disease Genetic Testing Market Share, Size, Trends, Industry Analysis Report, By Disease Type (Neurological Disorders, Immunological Disorders, Hematology Ailments, Endocrine & Metabolism Disorders, Cancer, Musculoskeletal Disorders, Cardiovascular Disorders, Dermatology Disorders, Others); By Technology; By Specialty; By End-Use; By Regions; Segment Forecast, 2020 – 2027” gives a detailed insight into current market dynamics and provides analysis on future market growth.
The growing need for on-time diagnosis of uncommon
disorders, rising prevalence of rare disorders, innovations in genomic testing,
and the focused approach of the market player’s in cost-effective treatments
are the key factors responsible for market growth. Moreover,
government-sponsored schemes are also expected to positively impact the market.
In February 2020, the government of India announced financial assistance of INR
15 lacs to the patients suffering from uncommon ailments under the Rashtriya
Arogaya Nidhi scheme for a one-time treatment.
The global rare disease genetic testing industry is
fragmented based on disease type, technology, specialty, end-use, and region.
In terms of disease type, the market is segmented into neurological disorders,
immunological disorders, hematology illnesses, endocrine & metabolism
ailments, cancer, musculoskeletal disorders, cardiovascular disorders,
dermatology illnesses, and others.
Download Sample Copy : https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/request-for-sample
Based on technology, the rare disease genetic
testing industry is further bifurcated into next-generation sequencing, array
technology, PCR-based testing, FISH, sanger sequencing, and karyotyping. Based
on specialty, the rare disease genetic testing industry is further bifurcated
into molecular, chromosomal, and biochemical genomic tests. Based on end-use,
the rare disease genomic testing industry is further bifurcated into research
laboratories & CROs, hospitals & clinics, and diagnostic laboratories.
Segment Highlights
·
Neurological ailments accounted for the largest
revenue share in 2019 on account of the increasing prevalence of neurologic
disorders across the globe and presence of numerous testing techniques
·
Based on technology, the next generation sequencing
segment is projected to constitute almost half of the market in 2027. The usage
of the technology in whole genome sequencing is the key factor responsible for
its segment’s growth.
·
Molecular tests are expected to account for the
highest revenue share by the end of 2027. The availability of advanced technologies
and ability to test ultra-rare disorders is expected to drive market growth.
·
Research laboratories & CROs accounted for the
largest revenue share in 2019 owing to the increasing number of tests and
growing occurrence of rare disorders across the developed economies
List of Key Players
·
Strand Life Sciences
·
Myriad Genetics
·
Quest Diagnostics Inc.
·
Centogene N.V.
·
Invitae Corporation
·
Baylor Genetics
·
Ambry Genetics
·
Macrogen, Inc.
·
Opko Health, Inc.
·
Color Genomics, Inc.
·
Health Network Laboratories
·
Preventiongenetics, Progenity, Inc.
·
Fulgent Genetics Inc.
·
Others
Do You Have Any Query Or Specific
Requirement? Ask to Our Industry Expert @ https://www.polarismarketresearch.com/industry-analysis/rare-disease-genetic-testing-market/speak-to-analyst
Polaris Market Research has segmented the rare
disease genetic testing market report on the basis of disease type, technology,
specialty, end-use, and region
Rare Disease Genetic Testing, Disease Type Outlook
(Revenue – USD Million, 2016 – 2027)
·
Neurological Disorders
·
Immunological Disorders
·
Hematology Ailments
·
Endocrine & Metabolism Disorders
·
Cancer
·
Musculoskeletal Disorders
·
Cardiovascular Disorders
·
Dermatology Disorders
·
Others
Rare Disease Genetic Testing, Technology Outlook
(Revenue – USD Million, 2016 – 2027)
·
Next Generation Sequencing
·
Whole Exome Sequencing
·
Whole Genome Sequencing
·
Array Technology
·
PCR-based Testing
·
FISH
·
Sanger Sequencing
·
Karyotyping
Rare Disease Genetic Testing, Specialty Outlook
(Revenue – USD Million, 2016 – 2027)
·
Molecular Genetic Tests
·
Chromosomal Genetic Tests
·
Biochemical Genetic Tests
Rare Disease Genetic Testing, Technology Outlook
(Revenue – USD Million, 2016 – 2027)
·
Research Laboratories & CROs
·
Hospitals & Clinics
·
Diagnostic Laboratories
Rare Disease Genetic Testing, Regional Outlook
(Revenue – USD Million, 2016 – 2027)
·
North America
o U.S.
o Canada
·
Europe
o France
o Germany
o UK
o Italy
o Spain
o Netherlands
o Austria
·
Asia Pacific
o China
o India
o Japan
o Malaysia
o South
Korea
o Indonesia
·
Central & South America
o Mexico
o Brazil
o Argentina
·
Middle East & Africa
o UAE
o Saudi
Arabia
o Israel
·
South Africa
